ID
37320
Description
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form includes Clinical Chemistry and Haematology lab examinations and results and is to be filled in at Screening, on Days 2 and 3 at 0 hrs and Day 3 at 24 hrs (i.e. Day 4 - 0 hrs) and at Follow-Up for all cohorts and for any repeat analyses.
Lien
https://clinicaltrials.gov/ct2/show/NCT00996840
Mots-clés
Versions (1)
- 16/07/2019 16/07/2019 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
16 juillet 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Local Laboratory - Clinical Chemistry and Haematology
- StudyEvent: ODM
Description
Clinical Chemistry Analysis
Alias
- UMLS CUI-1
- C0008000
- UMLS CUI-2
- C0022885
Description
Fill in the following items for each analysed feature at all visits (except for repeat assessments). The following items are not mandatory for Days 2 and 3 for all cohorts: 16 = Prothrombin Time (PT) 17 = Partial Thromboplastin Time (PTT) 19 = International normalized ratio (INR) 22 = Arterial Blood pH 23 = Serum Estradiol item 22 = Arterial Blood pH is not mandatory for Follow-up Select the appropriate feature for Repeat Analysis. The inclusion of 23 = Serum Estradiol during Screening and Follow-Up is a change to the study.
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C0022885
Description
Clinical chemistry result type
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C0332307
Description
if applicable
Type de données
float
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C2347373
Description
if applicable
Type de données
text
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C2350015
Description
Haematology Lab Analysis
Alias
- UMLS CUI-1
- C0022885
- UMLS CUI-2
- C0018941
Description
Select the appropriate feature for Repeat Analysis At all other visits, fill in the following items for each analysed feature.
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0022885
- UMLS CUI [1,2]
- C0018941
Description
Haematology Lab result type
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0022885
- UMLS CUI [1,2]
- C0018941
- UMLS CUI [1,3]
- C1274040
- UMLS CUI [1,4]
- C0332307
Description
if applicable
Type de données
float
Alias
- UMLS CUI [1,1]
- C0018941
- UMLS CUI [1,2]
- C2347373
Description
if applicable
Type de données
text
Alias
- UMLS CUI [1,1]
- C0018941
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C2350015
Similar models
Local Laboratory - Clinical Chemistry and Haematology
- StudyEvent: ODM
C0022885 (UMLS CUI-2)
C0200345 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C0200345 (UMLS CUI [1,2])
C0022885 (UMLS CUI-2)
C0022885 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347373 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,3])
C0018941 (UMLS CUI-2)
C0018941 (UMLS CUI [1,2])
C0018941 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,4])
C2347373 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,3])
Aucun commentaire